Human gut microbiota and its relationship to health and disease

Nutrition Reviews

Volumn 69, Issue 7, 2011, Pages 392-403

  Wallace, Taylor C ^a   Guarner, Francisco ^b   Madsen, Karen ^c   Cabana, Michael D ^d   Gibson, Glenn ^e   Hentges, Eric ^a   Sanders, Mary Ellen ^f  

^a International Life Sciences Institute   (United States)

^b HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^c UNIVERSITY OF ALBERTA   (Canada)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e UNIVERSITY OF READING   (United Kingdom)

^f International Scientific Association for Probiotics and Prebiotics   (United States)

Author keywords

Clinical guidelines; Gut microbiota; Health; Intervention; Prebiotic; Probiotic

Indexed keywords

ANTIBIOTIC AGENT; FRUCTOSE OLIGOSACCHARIDE; GALACTOSE OLIGOSACCHARIDE; INULIN; PREBIOTIC AGENT; PROBIOTIC AGENT; PROTEASOME INHIBITOR; SYNBIOTIC AGENT; VITAMIN B GROUP; VITAMIN K GROUP;

ANTIMICROBIAL ACTIVITY; APOPTOSIS; ARTICLE; ASTHMA; ATOPIC DERMATITIS; BACTERIAL COLONIZATION; BACTERIAL INFECTION; BACTERIAL STRAIN; BATCH FERMENTATION; CLINICAL RESEARCH; CLINICAL TRIAL (TOPIC); COLONY FORMING UNIT; CONSTIPATION; DIARRHEA; DIET SUPPLEMENTATION; DRUG EFFICACY; DRUG INHIBITION; DRUG MEGADOSE; DRUG METABOLISM; DRUG SAFETY; DRUG USE; ENTERITIS; ENTEROPATHY; EXTRAINTESTINAL DISORDER; FOOD ALLERGY; GASTROINTESTINAL DISEASE; GASTROINTESTINAL TRACT; HEALTH; HEALTH PROMOTION; HUMAN; IMMUNE SYSTEM; IN VITRO STUDY; IN VIVO STUDY; INFANTILE DIARRHEA; INFLAMMATION; INTERVENTION STUDY; INTESTINE FLORA; IRRITABLE COLON; LACTOSE INTOLERANCE; LIVER DISEASE; MEDICAL SPECIALIST; METABOLIC SYNDROME X; MUCOSAL IMMUNITY; MYCOSIS; NECROTIZING ENTEROCOLITIS; NONHUMAN; NORTH AMERICA; PATIENT COMPLIANCE; PRACTICE GUIDELINE; PSORIASIS; RHEUMATOID ARTHRITIS; SEPSIS; SYSTEMIC INFECTION; TREATMENT OUTCOME; URINARY TRACT INFECTION; VAGINITIS; VITAMIN SUPPLEMENTATION;

ANIMALS; GASTROINTESTINAL DISEASES; HEALTH STATUS; HUMANS; METABOLIC SYNDROME X; PRACTICE GUIDELINES AS TOPIC; PREBIOTICS; PROBIOTICS;

EID: 79960067123     PISSN: 00296643     EISSN: 17534887     Source Type: Journal    
DOI: 10.1111/j.1753-4887.2011.00402.x     Document Type: Article

References (95)

1. Pasteur L. Observations relatives à la note précédente de M. Duclaux. CR Acad Sci (Paris). 1885;100:68.
2. Wostmann BS. The germ-free animal in nutritional studies. Annu Rev Nutr. 1981;1:257-279.
3. Schopf JW. Fossil evidence of Archaean life. Philos Trans R Soc Lond B Biol Sci. 2006;361:869-885.
4. Buckley MR. Microbial Communities: From Life Apart to Life Together. Washington, DC: American Academy of Microbiology; 2003:Available at: Accessed 23 September 2010
5. Fuller R, ed. Probiotics: The Scientific Basis. London, UK: Chapman & Hall; 1992.
6. Gibson GR, Roberfroid MB. Dietary modulation of the colonic microbiota: Introducing the concept of prebiotics. J Nutr. 1995;125:1401-1412.
7. Gibson GR, Probert HM, van Loo JAE, Rastall RA, Roberfroid MB. Dietary modulation of the human colonic microbiota: Updating the concept of prebiotics. Nutr Res Rev. 2004;17:259-275.
8. Kerckhoffs APM, Samson M, van Berge Henegouwen GP, Akkermans LMA, Nieuwenhuijs VB, Visser MR. Sampling microbiota in the human gastrointestinal tract. In: Ouwehand A, Vaughan EE, eds. Gastrointestinal Microbiology. New York, NY: Taylor & Francis Ltd; 2006:25-50.
9. Chaia AP, Oliver G. Intestinal microflora and metabolic activity. In: Feller R, Perdigon G, eds. Gut Flora, Nutrition, Immunity, and Health. Oxford, UK: Blackwell Publishers; 2003:77-98.
10. McCracken VJ, Gaskins HR. Probiotics and the immune system. In: Tannock GW, ed. Probiotics: A Critical Review. Wymondam, UK: Horizon Scientific Press; 1999:85-111.
11. Lievin V, Peoffer I, Hudault S, etal. Bifidobacterium strains from resident infant human gastrointestinal microflora exert antimicrobial activity. Gut. 2000;47:646-652.
12. Collado MC, Gueimonde M, Hernandez M, Sanz Y, Salminen S. Adhesion of selected Bifidobacterium strains to human intestinal mucus and its role in enteropathogen exlusion. J Food Prot. 2005;68:2672-2678.
13. Didierlaurent A, Sirard JC, Kraehenbuhl JP, Neutra MR. How the gut senses its content. Cell Microbiol. 2001;4:61-72.
14. Collado MC, Meriluoto J, Salminen S. In vitro analysis of probiotic strains combinations to inhibit pathogen adhesion to human intestinal mucus. Food Res Int. 2007;40:629-636.
15. Ndagijimana M, Laghi L, Vitali B, Placucci G, Brigidi P, Guerzoni ME. Effect of a synbiotic food consumption on human gut metabolic profiles evaluated by (1)H Nuclear Magnetic Resonance spectroscopy. Int J Food Microbiol. 2009;134:147-153.
16. Sierra S, Lara-Villoslada F, Sempere L, Olivares M, Boza J, Xaus J. Intestinal and immunological effects of daily oral administration of Lactobacillus salivarius CECT5713 to healthy adults. Anaerobe. 2010;16:195-200.
17. Perez N, Iannicelli JC, Girard-Bosch C, etal. Effect of probiotic supplementation on immunoglobulins, isoagglutinins and antibody response in children of low socio-economic status. Eur J Nutr. 2010;49:173-179.
18. Martinez-Canavate A, Sierra S, Lara-Villoslada F, etal. A probiotic dairy product containing L. gasseri CECT5714 and L. coryniformis CECT5711 induces immunological changes in children suffering from allergy. Pediatr Allergy Immunol. 2009;20:592-600.
19. Baron M. A patented strain of Bacillus coagulans increased immune response to viral challenge. Postgrad Med. 2009;121:114-118.
20. West CE, Hammarstrom ML, Hernell O. Probiotics during weaning reduce the incidence of eczema. Pediatr Allergy Immunol. 2009;20:430-437.
21. Gibson RA, Barclay D, Marshall H, Moulin J, Maire JC, Makrides M. Safety of supplementing infant formula with long-chain polyunsaturated fatty acids and Bifidobacterium lactis in term infants: a randomised controlled trial. Br J Nutr. 2009;101:1706-1713.
22. Mondel M, Schroeder BO, Zimmermann K, etal. Probiotic E. coli treatment mediates antimicrobial human beta-defensin synthesis and fecal excretion in humans. Mucosal Immunol. 2009;2:166-172.
23. Woo SI, Kim JY, Lee YJ, Kim NS, Hahn YS. Effect of Lactobacillus sakei supplementation in children with atopic eczema-dermatitis syndrome. Ann Allergy Asthma Immunol. 2010;104:343-348.
24. Ng SC, Plamondon S, Kamm MA, etal. Immunosuppressive effects via human intestinal dendritic cells of probiotic bacteria and steroids in the treatment of acute ulcerative colitis. Inflamm Bowel Dis. 2010;16:1286-1298.
25. Kim JY, Kwon JH, Ahn SH, etal. Effect of probiotic mix (Bifidobacterium bifidum, Bifidobacterium lactis, Lactobacillus acidophilus) in the primary prevention of eczema: a double-blind, randomized, placebo-controlled trial. Pediatr Allergy Immunol. 2010;21:e386-e393.
26. Fujimori S, Gudis K, Mitsui K, etal. A randomized controlled trial on the efficacy of synbiotic versus probiotic or prebiotic treatment to improve the quality of life in patients with ulcerative colitis. Nutrition. 2009;25:520-525.
27. Hosoki K, Nakamura A, Nagao M, etal. Differential activation of eosinophils by "probiotic"Bifidobacterium bifidum and "pathogenic"Clostridium difficile. Int Arch Allergy Immunol. 2010;152:83-89.
28. Dong H, Rowland I, Tuohy KM, Thomas LV, Yaqoob P. Selective effects of Lactobacillus casei Shirota on T cell activation, natural killer cell activity and cytokine production. Clin Exp Immunol. 2009;161:378-388.
29. Lopez P, Gueimonde M, Margolles A, Suarez A. Distinct Bifidobacterium strains drive different immune responses in vitro. Int J Food Microbiol. 2010;138:157-165.
30. van Hoffen E, Korthagen NM, de Kivit S, etal. Exposure of intestinal epithelial cells to UV-killed Lactobacillus GG but not Bifidobacterium breve enhances the effector immune response in vitro. Int Arch Allergy Immunol. 2010;152:159-168.
31. Chiu YH, Hsieh YJ, Liao KW, Peng KC. Preferential promotion of apoptosis of monocytes by Lactobacillus casei rhamnosus soluble factors. Clin Nutr. 2010;29:131-140.
32. Paolillo R, Romano Carratelli C, Sorrentino S, Mazzola N, Rizzo A. Immunomodulatory effects of Lactobacillus plantarum on human colon cancer cells. Int Immunopharmacol. 2009;9:1265-1271.
33. Llopis M, Antolin M, Carol M, etal. Lactobacillus casei downregulates commensals' inflammatory signals in Crohn's disease mucosa. Inflamm Bowel Dis. 2009;15:275-283.
34. Zhou Y, Qin H, Zhang M, etal. Lactobacillus plantarum inhibits intestinal epithelial barrier dysfunction induced by unconjugated bilirubin. Br J Nutr. 2010;104:390-401.
35. Miyauchi E, Morita H, Tanabe S. Lactobacillus rhamnosus alleviates intestinal barrier dysfunction in part by increasing expression of zonula occludens-1 and myosin light-chain kinase in vivo. J Dairy Sci. 2009;92:2400-2408.
36. Mathias A, Duc M, Favre L, Benyacoub J, Blum S, Corthesy B. Potentiation of polarized intestinal Caco-2 cell responsiveness to probiotics complexed with secretory IgA. J Biol Chem. 2010;285:33906-33913.
37. Kim Y, Oh S, Yun HS, Kim SH. Cell-bound exopolysaccharide from probiotic bacteria induces autophagic cell death of tumour cells. Lett Appl Microbiol. 2010;51:123-130.
38. Im E, Choi YJ, Kim CH, Fiocchi C, Pothoulakis C, Rhee SH. The angiogenic effect of probiotic Bacillus polyfermenticus on human intestinal microvascular endothelial cells is mediated by IL-8. Am J Physiol Gastrointest Liver Physiol. 2009;297:G999-G1008.
39. Chon H, Choi B. The effects of a vegetable-derived probiotic lactic acid bacterium on the immune response. Microbiol Immunol. 2010;54:228-236.
40. Yang H, Liu A, Zhang M, etal. Oral administration of live Bifidobacterium substrains isolated from centenarians enhances intestinal function in mice. Curr Microbiol. 2009;59:439-445.
41. Martin F, Sprenger N, Yap IK, etal. Panorganismal gut microbiome-host metabolic crosstalk. J Proteome Res. 2009;8:2090-2105.
42. Adam E, Delbrassine L, Bouillot C, etal. Probiotic Escherichia coli Nissle 1917 activates DC and prevents house dust mite allergy through a TLR4-dependent pathway. Eur J Immunol. 2010;40:1995-2005.
43. Rumbo M, Anderle P, Didierlaurent A, etal. How the gut links innate and adaptive immunity. Ann N Y Acad Sci. 2004;1029:16-21.
44. Collier-Hyams LS, Neish AS. Innate immune relationship between commensal flora and the mammalian intestinal epithelium. Cell Mol Life Sci. 2005;62:1339-1348.
45. Uematsu S, Akira S. Toll-like receptors and innate immunity. J Mol Med. 2006;84:712-725.
46. Cario E, Gerken G, Podolsky DK. Toll-like receptor 2 controls mucosal inflammation by regulating epithelial barrier function. Gastroenterology. 2007;132:1359-1374.
47. Petrof EO, Kojima K, Ropeleski MJ, etal. Probiotics inhibit nuclear factor-kappaB and induce heat shock proteins in colonic epithelial cells through proteasome inhibition. Gastroenterology. 2004;127:1474-1487.
48. Madsen K, Cornish A, Soper P, etal. Probiotic bacteria enhance murine and human intestinal epithelial barrier function. Gastroenterology. 2001;121:580-591.
49. Mukherjee P, Dani A, Bhatia S, etal. Efficient presentation of both cytosolic and endogenous transmembrane protein antigens on MHC class II is dependent on cytoplasmic proteolysis. J Immunol. 2001;167:2632-2641.
50. Eldridge AG, O'Brien T. Therapeutic strategies within the ubiquitin proteasome system. Cell Death Differ. 2010;17:4-13.
51. Elliott PJ, Zollner TM, Boehncke WH. Proteasome inhibition: a new anti-inflammatory strategy. J Mol Med. 2003;81:235-245.
52. Jijon H, Backer J, Diaz H, etal. DNA from probiotic bacteria modulates murine and human epithelial and immune function. Gastroenterology. 2004;126:1358-1373.
53. Petrof EO, Claud EC, Sun J, etal. Bacteria-free solution derived from Lactobacillus plantarum inhibits multiple NF-kappaB pathways and inhibits proteasome function. Inflamm Bowel Dis. 2009;15:1537-1547.
54. de LeBlanc Ade M, Castillo NA, Perdigon G. Anti-infective mechanisms induced by a probiotic Lactobacillus strain against Salmonella enterica serovar Typhimurium infection. Int J Food Microbiol. 2010;138:223-231.
55. Paineau D, Carcano D, Leyer G, etal. Effects of seven potential probiotic strains on specific immune responses in healthy adults: a double-blind, randomized, controlled trial. FEMS Immunol Med Microbiol. 2008;53:107-113.
56. Macpherson AJ, Slack E. The functional interactions of commensal bacteria with intestinal secretory IgA. Curr Opin Gastroenterol. 2007;23:673-678.
57. Kwon HK, Lee CG, So JS, etal. Generation of regulatory dendritic cells and CD4+Foxp3+ T cells by probiotics administration suppresses immune disorders. Proc Natl Acad Sci U S A. 2010;107:2159-2164.
58. Hart AL, Lammers K, Brigidi P, etal. Modulation of human dendritic cell phenotype and function by probiotic bacteria. Gut. 2004;53:1602-1609.
59. Christensen HR, Frokiaer H, Pestka JJ. Lactobacilli differentially modulate expression of cytokines and maturation surface markers in murine dendritic cells. J Immunol. 2002;168:171-178.
60. Ewaschuk J, Diaz H, Meddings L, etal. Secreted bioactive factors from Bifidobacterium infantis enhance epithelial cell barrier function. Am J Physiol. 2008;295:G1025-G1034.
61. Resta-Lenert S, Barrett KE. Live probiotics protect intestinal epithelial cells from the effects of infection with enteroinvasive Escherichia coli (EIEC). Gut. 2003;52:988-997.
62. Otte JM, Podolsky DK. Functional modulation of enterocytes by gram-positive and gram-negative microorganisms. Am J Physiol Gastrointest Liver Physiol. 2004;286:G613-G626.
63. Caballero-Franco C, Keller K, De Simone C, Chadee K. The VSL#3 probiotic formula induces mucin gene expression and secretion in colonic epithelial cells. Am J Physiol Gastrointest Liver Physiol. 2007;292:G315-G322.
64. Petrof EO, Ciancio MJ, Chang EB. Role and regulation of intestinal epithelial heat shock proteins in health and disease. Chin J Dig Dis. 2004;5:45-50.
65. Tao Y, Drabik KA, Waypa TS, etal. Soluble factors from Lactobacillus GG activate MAPKs and induce cytoprotective heat shock proteins in intestinal epithelial cells. Am J Physiol Cell Physiol. 2006;290:C1018-C1030. erratum 2006;291:C194.
66. Fujiya M, Musch MW, Nakagawa Y, etal. The Bacillus subtilis quorum-sensing molecule CSF contributes to intestinal homeostasis via OCTN2, a host cell membrane transporter. Cell Host Microbe. 2007;1:299-308.
67. Yan F, Polk DB. Probiotic bacterium prevents cytokine-induced apoptosis in intestinal epithelial cells. J Biol Chem. 2002;277:50959-50965.
68. Yan F, Cao H, Cover TL, Whitehead R, Washington MK, Polk DB. Soluble proteins produced by probiotic bacteria regulate intestinal epithelial cell survival and growth. Gastroenterology. 2007;132:562-575.
69. Schlee M, Harder J, Koten B, Stange EF, Wehkamp J, Fellermann K. Probiotic lactobacilli and VSL#3 induce enterocyte beta-defensin 2. Clin Exp Immunol. 2008;151:528-535.
70. Wehkamp J, Harder J, Wehkamp K, etal. NF-kappaB- and AP-1-mediated induction of human beta defensin-2 in intestinal epithelial cells by Escherichia coli Nissle 1917: a novel effect of a probiotic bacterium. Infect Immun. 2004;72:5750-5758.
71. Collado MC, Meriluoto J, Salminen S. Role of commercial probiotic strains against human pathogen adhesion to intestinal mucus. Lett Appl Microbiol. 2007;45:454-460.
72. Candela M, Seibold G, Vitali B, Lachenmaier S, Eikmanns BJ, Brigidi P. Real-time PCR quantification of bacterial adhesion to Caco-2 cells: competition between bifidobacteria and enteropathogens. Res Microbiol. 2005;156:887-895.
73. Roselli M, Finamore A, Britti MS, Mengheri E. Probiotic bacteria Bifidobacterium animalis MB5 and Lactobacillus rhamnosus GG protect intestinal Caco-2 cells from the inflammation-associated response induced by enterotoxigenic Escherichia coli K88. Br J Nutr. 2006;95:1177-1184.
74. Sherman PM, Johnson-Henry KC, Yeung HP, Ngo PS, Goulet J, Tompkins TA. Probiotics reduce enterohemorrhagic Escherichia coli O157:H7- and enteropathogenic E. coli O127:H6-induced changes in polarized T84 epithelial cell monolayers by reducing bacterial adhesion and cytoskeletal rearrangements. Infect Immun. 2005;73:5183-5188.
75. Mukai T, Kaneko S, Matsumoto M, Ohori H. Binding of Bifidobacterium bifidum and Lactobacillus reuteri to the carbohydrate moieties of intestinal glycolipids recognized by peanut agglutinin. Int J Food Microbiol. 2004;90:357-362.
76. Tallon R, Arias S, Bressollier P, Urdaci MC. Strain- and matrix-dependent adhesion of Lactobacillus plantarum is mediated by proteinaceous bacterial compounds. J Applied Microbiol. 2007;102:442-451.
77. Martin FP, Wang Y, Sprenger N, etal. Probiotic modulation of symbiotic gut microbial-host metabolic interactions in a humanized microbiome mouse model. Mol Syst Biol. 2008;4:article no. 157.
78. Sonnenburg JL, Chen CT, Gordon JI. Genomic and metabolic studies of the impact of probiotics on a model gut symbiont and host. PLoS Biol. 2006;4:e413.
79. Council for Agricultural Science and Technology (CAST). Probiotics: Their Potential to Impact Human Health. Issue Paper 36. Ames, IA: CAST; 2007:Available at: Accessed 3 July 2010.
80. Tissier H. Tritement des infections intestinales par la methode de translormation de la flore bacterienne de L'intestin. CR Soc Bio. 1906;60:359-361.
81. Cabana MD, Shane AL, Chao C, Oliva-Hemker M. Probiotics in primary care pediatrics. Clin Pediatr (Phila). 2006;45:405-410.
82. McFarland LV. Systematic review and meta-analysis of Saccharomyces boulardii in adult patients. World J Gastroentrol. 2010;16:2202-2222.
83. Bode L. Human milk oligosaccharides: prebiotics and beyond. Nutr Rev. 2009;67(Suppl 2):S183-S191.
84. Oelschlaeger TA. Mechanisms of probiotic actions: a review. Int J Med Microbiol. 2010;300:57-62.
85. Xiao JZ, Kondo S, Yanagisawa N, etal. Effect of probiotic Bifidobacterium longum BB536 [corrected] in relieving clinical symptoms and modulating plasma cytokine levels of Japanese cedar pollinosis during the pollen season. A randomized double-blind, placebo-controlled trial. J Investig Allergol Clin Immunol. 2006;16:86-93.
86. Caglar E, Cildir SK, Ergeneli S, Sandalli N, Twetman S. Salivary mutans streptococci and lactobacilli levels after ingestion of the probiotic bacterium Lactobacillus reuteri ATCC 55730 by straws or tablets. Acta Odont Scand. 2006;64:314-318.
87. Kalliomäki M, Salminen S, Poussa T, Arvilommi H, Isolauri E. Probiotics and prevention of atopic disease: 4-year follow-up of a randomised placebo-controlled trial. Lancet. 2003;361:1869-1871.
88. Gionchetti P, Rizzello F, Morselli C, etal. High-dose probiotics for the treatment of active pouchitis. Dis Colon Rectum. 2007;50:2075-2084.
89. Marcobal A, Underwood MA, Mills DA. Rapid determination of the bacterial composition of commercial probiotic products by terminal restriction fragment length polymorphism analysis. J Pediatr Gastroenterol Nutr. 2008;46:608-611.
90. Osterberg L, Blaschke T. Adherence to medication. N Engl J Med. 2005;353:487-497.
91. Claxton AJ, Cramer J, Pierce C. A systematic review of the associations between dose regimens and medication compliance. Clin Ther. 2001;23:1296-1310.
92. Adams MR, Marteau P. On the safety of lactic acid bacteria. Int J Food Micro. 1995;27:263-264.
93. Saxelin M, Chuang NH, Chassy B, etal. Lactobacilli and bacteremia in southern Finland, 1989-1992. Clin Infect Dis. 1996;22:564-566.
94. Salminen MK, Tynkkynen S, Rautelin H, etal. Lactobacillus bacteremia during a rapid increase in probiotic use of Lactobacillus rhamnosus GG in Finland. Clin Infect Dis. 2002;35:1155-1160.
95. Boyle RJ, Robins-Browne RM, Tang ML. Probiotic use in clinical practice: what are the risks? Am J Clin Nutr. 2006;83:1256-1264.